ING Groep NV acquired a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 13,470 shares of the biopharmaceutical company’s stock, valued at approximately $6,023,000.

A number of other institutional investors have also recently made changes to their positions in the business. Fieldpoint Private Securities LLC acquired a new stake in Regeneron Pharmaceuticals in the 2nd quarter valued at about $130,000. Sterling Investment Advisors Ltd. grew its stake in Regeneron Pharmaceuticals by 11.2% in the 2nd quarter. Sterling Investment Advisors Ltd. now owns 278 shares of the biopharmaceutical company’s stock valued at $137,000 after acquiring an additional 28 shares during the last quarter. FNY Partners Fund LP grew its stake in Regeneron Pharmaceuticals by 200.0% in the 2nd quarter. FNY Partners Fund LP now owns 300 shares of the biopharmaceutical company’s stock valued at $147,000 after acquiring an additional 200 shares during the last quarter. IFP Advisors Inc grew its stake in Regeneron Pharmaceuticals by 33.2% in the 2nd quarter. IFP Advisors Inc now owns 385 shares of the biopharmaceutical company’s stock valued at $189,000 after acquiring an additional 96 shares during the last quarter. Finally, Virtu KCG Holdings LLC acquired a new stake in Regeneron Pharmaceuticals in the 2nd quarter valued at about $206,000. Institutional investors own 66.51% of the company’s stock.

A number of equities research analysts recently commented on the stock. Morgan Stanley reissued an “equal weight” rating and issued a $450.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Wednesday, August 23rd. Canaccord Genuity reissued a “buy” rating on shares of Regeneron Pharmaceuticals in a research note on Monday, October 16th. Barclays PLC cut shares of Regeneron Pharmaceuticals from an “equal weight” rating to an “underweight” rating and lowered their price objective for the company from $450.00 to $395.00 in a research note on Friday, October 20th. Oppenheimer Holdings, Inc. reissued a “hold” rating on shares of Regeneron Pharmaceuticals in a research note on Wednesday, September 27th. Finally, Leerink Swann reaffirmed an “outperform” rating and set a $580.00 price target (up from $573.00) on shares of Regeneron Pharmaceuticals in a research note on Wednesday, August 9th. Two analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Hold” and an average price target of $475.34.

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ REGN) traded up $3.10 during mid-day trading on Thursday, hitting $387.54. 367,500 shares of the stock traded hands, compared to its average volume of 897,789. The stock has a market cap of $41,303.85, a price-to-earnings ratio of 33.28, a P/E/G ratio of 1.51 and a beta of 1.56. Regeneron Pharmaceuticals, Inc. has a 1-year low of $340.09 and a 1-year high of $543.55. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.07 and a current ratio of 3.63.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported $3.99 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $3.83 by $0.16. The business had revenue of $1.50 billion for the quarter, compared to analyst estimates of $1.45 billion. Regeneron Pharmaceuticals had a net margin of 23.17% and a return on equity of 25.73%. The company’s revenue was up 23.0% on a year-over-year basis. During the same period in the prior year, the firm posted $3.13 EPS. equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 13.55 earnings per share for the current year.

In other news, CFO Robert E. Landry sold 189 shares of the stock in a transaction dated Tuesday, September 5th. The shares were sold at an average price of $501.06, for a total transaction of $94,700.34. Following the transaction, the chief financial officer now directly owns 10,099 shares in the company, valued at approximately $5,060,204.94. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Robert E. Landry sold 427 shares of the stock in a transaction dated Thursday, August 31st. The stock was sold at an average price of $493.43, for a total transaction of $210,694.61. Following the transaction, the senior vice president now owns 9,099 shares in the company, valued at $4,489,719.57. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 4,779 shares of company stock worth $2,248,467. Insiders own 10.80% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “ING Groep NV Invests $6.02 Million in Regeneron Pharmaceuticals, Inc. (REGN) Stock” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/11/23/ing-groep-nv-invests-6-02-million-in-regeneron-pharmaceuticals-inc-regn-stock.html.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Stock Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.